Scienture Holdings, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SCNX research report →
Companywww.trxadehealth.com
TRxADE HEALTH, Inc. operates as health services IT company. It offers an online web-based buying and selling platform for licensed pharmaceutical wholesalers to sell brand, generic, and non-drug products and services to government organizations, hospitals, clinics and independent pharmacies.
- CEO
- Shankar Hariharan
- IPO
- 2014
- Employees
- 14
- HQ
- Tampa, FL, US
Price Chart
Valuation
- Market Cap
- $6.05M
- P/E
- -3.81
- P/S
- 0.11
- P/B
- 0.00
- EV/EBITDA
- 89.07
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 95.48%
- Op Margin
- -27.19%
- Net Margin
- -73.75%
- ROE
- -0.12%
- ROIC
- -0.02%
Growth & Income
- Revenue
- $431.61K · 215.87%
- Net Income
- $-41,512,264 · -557.90%
- EPS
- $-2.70 · -200.37%
- Op Income
- $-16,244,792
- FCF YoY
- -93632.98%
Performance & Tape
- 52W High
- $2.60
- 52W Low
- $0.24
- 50D MA
- $0.40
- 200D MA
- $0.67
- Beta
- 3.17
- Avg Volume
- 3.04M
Get TickerSpark's AI analysis on SCNX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 20, 26 | Shankar Hariharan | other | 500,000 |
| Oct 1, 25 | Shankar Hariharan | other | 300,000 |
| Apr 14, 25 | Shankar Hariharan | other | 750,000 |
| Sep 19, 24 | Shankar Hariharan | other | 1,916,816 |
| Mar 10, 25 | Shankar Hariharan | other | 30,000 |
| Sep 19, 24 | Shankar Hariharan | other | 356,480 |
| Sep 19, 24 | Shankar Hariharan | other | 356,480 |
| Feb 20, 26 | Narasimhan Mani | other | 500,000 |
| Sep 19, 24 | Narasimhan Mani | other | 1,357,538 |
| Mar 10, 25 | Narasimhan Mani | other | 20,000 |
Our SCNX Coverage
We haven't published any research on SCNX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SCNX Report →